Durlobactam
- Generic Name
- Durlobactam
- Brand Names
- Xacduro
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O6S
- CAS Number
- 1467829-71-5
- Unique Ingredient Identifier
- PSA33KO9WA
- Background
Durlobactam is under investigation in clinical trial NCT03894046 (Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex).
- Indication
Durlobactam is co-packaged with sulbactam as a single combination product, and is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.
- Associated Conditions
- Nosocomial Pneumonia caused by Acinetobacter Baumannii-calcoaceticus Complex, Ventilator Associated Bacterial Pneumonia (VABP) caused by Acinetobacter Baumannii-calcoaceticus Complex
- Associated Therapies
- -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Entasis Therapeutics
- Target Recruit Count
- 207
- Registration Number
- NCT03894046
- Locations
- 🇹🇷
Entasis Research Site 2, Ankara, Turkey
🇷🇺Entasis Research Site 3, Novosibirsk, Russian Federation
🇹🇷Entasis Research Site, Trabzon, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.